Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 28, 2011

View Archived Issues

C16orf74 mRNA levels correlate with progression of NMIBC

Interim phase I data presented on FG-3019 in pancreatic cancer

Morphine-6-O-sulfate shows potent analgesic activity and favorable toxicity in models of pain

Telomere inhibitor TMPyP4 inhibits sarcoma cell growth

FDA grants BMS and sanofi-aventis additional 6 months of exclusivity for Plavix

ARQ-197/irinotecan/cetuximab combination is safe and shows antitumor activity in colorectal cancer

IMTM's dual DPP IV/AP-N inhibitor reduces clinical signs of EAE

CMC-PE hydrogel enhances nerve regeneration after experimental peripheral nerve surgery

New sodium channel blockers claimed by University of Greenwich

Actient Pharmaceuticals acquires Timm Medical Technologies

Betagenon discloses novel AMPK activators

NuVax licenses immune-gene therapeutics technology

New phase II trial evaluates ReoT3D plus carboplatin/paclitaxel in pancreatic cancer

FDA sets PDUFA date for Remoxy NDA resubmission

Leo Pharma patents new inhibitors of JAK1, JAK2 and JAK3

Clinical development of Pluristem Therapeutics' PLX-PAD advances

Regadenoson approved in E.U. as an aid to diagnose CAD

Galderma claims novel inhibitors of ADAM 17

Gilead Sciences presents highlights of fourth quarter 2010

Amgen divulges novel PI3K-delta inhibitors

ALK-Abello and Torii Pharma enter license agreement for allergy immunotherapies

Endo Pharma and Orion enter into oncology collaboration

Phase III EURTAC trial of Tarceva in NSCLC meets primary endpoint

UMMS and Lundbeck to codevelop targeted RNAi therapy for Huntington's disease

Mitsubishi Tanabe Pharma and Nycomed terminate roflumilast collaboration in Japan

Phase III data reported on BSI-201 in metastatic triple-negative breast cancer

Plexxikon begins first of two phase I trials of PLX-5622 and reports on PLX-3397

Actelion and GSK discontinue phase III development of almorexant

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...